{"schema_version":"secwatch.filing_event.v1","accession":"0001618835-23-000014","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.850318+00:00","generated_at":"2026-06-18T07:05:36.071006+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Biosciences CFO Justin J. File resigns; Albert Altro appointed interim CFO","bullets":["Justin J. File resigned as CFO effective April 3, 2023, to pursue other opportunities; no disagreement with company.","Albert Altro, with over 30 years of financial experience, appointed interim CFO on March 6, 2023.","Altro compensated at $275-$450/hour via engagement with his firm Traverse LLC; $40,000 retainer paid.","Company issued a press release on March 9, 2023, announcing the changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001618835-23-000014","json":"https://secwatch.observer/filing/0001618835-23-000014.json","markdown":"https://secwatch.observer/filing/0001618835-23-000014.md","text":"https://secwatch.observer/filing/0001618835-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/evfm-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:05:36.071006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f397e1ef6","claim":"Justin J. File resigned as Chief Financial Officer at Evofem Biosciences, Inc..","evidence_excerpt":"On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"74a77be9f0","claim":"Albert Altro was appointed as Chief Financial Officer at Evofem Biosciences, Inc..","evidence_excerpt":"On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}